More than one million sanitary masks, food, and personal protection equipment arrived Sunday in Cuba as part of the humanitarian aid sent by Russian President Vladimir Putin.
The Cuban Center for State Control of Medicines, Equipment and Medical Devices approved the phase I/II clinical trial to evaluate the safety and immunogenicity of the vaccine candidate Mambisa -intranasal- and the Abdala vaccine -intramuscular-, a study to boost immunity in convalescents of COVID-19.
The efficacy of the Soberana 02 vaccine candidate in its three-dose schedule together with Soberana Plus is 91.2%, which exceeds the World Health Organization (WHO) requirements for a vaccine candidate against COVID-19 to become a vaccine, which is 50%.
Design, obtaining and preclinical assessment of Cuban anti-Covid Soberana 02 vaccine candidate reached the headlines of the US magazine ACS Chemical Biology, paving the way for other antiviral vaccines.